Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2023

Open Access 01-12-2023 | Anemia | Research

Association of complication of type 2 diabetes mellitus with hemodynamics and exercise capacity in patients with heart failure with preserved ejection fraction: a case–control study in individuals aged 65–80 years

Authors: Yousuke Sugita, Katsuhiko Ito, Yui Yoshioka, Satoshi Sakai

Published in: Cardiovascular Diabetology | Issue 1/2023

Login to get access

Abstract

Background

Type 2 diabetes mellitus (T2DM) is a frequently observed complication in patients with heart failure with preserved ejection fraction (HFpEF). Although a characteristic finding in such patients is a decrease in objective exercise capacity represented by peak oxygen uptake (peakVO2), exercise capacity and its predictors in HFpEF with T2DM remain not clearly understood. This case–control study aimed to investigate the association between exercise capacity and hemodynamics indicators and T2DM comorbidity in patients with HFpEF aged 65–80 years.

Methods

Ninety-nine stable outpatients with HFpEF and 50 age-and-sex-matched controls were enrolled. Patients with HFpEF were classified as HFpEF with T2DM (n = 51, median age, 76 years) or without T2DM (n = 48, median age, 76 years). The peakVO2 and ventilatory equivalent versus carbon dioxide output slope (VE vs VCO2 slope) were measured by cardiopulmonary exercise testing. The peak heart rate (HR) and peak stroke volume index (SI) were measured using impedance cardiography, and the estimated arteriovenous oxygen difference (peak a-vO2 diff) was calculated with Fick's equation. The obtained data were compared among the three groups using analysis of covariance adjusted for the β-blocker medication, presence or absence of sarcopenia, and hemoglobin levels in order to determine the T2DM effects on exercise capacity and hemodynamics in patients with HFpEF.

Results

In HFpEF with T2DM compared with HFpEF without T2DM and the controls, the prevalence of sarcopenia, chronotropic incompetence, and anemia were significantly higher (p < 0.001). The peakVO2 (Controls 23.5 vs. without T2DM 15.1 vs. with T2DM 11.6 mL/min/kg), peak HR (Controls 164 vs. without T2DM 132 vs. with T2DM 120 bpm/min), peak a-vO2 (Controls 13.1 vs without T2DM 10.6 vs with T2DM 8.9 mL/100 mL), and VE vs VCO2 slope (Controls 33.2 vs without T2DM 35.0 vs with T2DM 38.2) were significantly worsened in patients with HFpEF with T2DM (median, p < 0.001). There was no significant difference in peak SI among the three groups.

Conclusions

Our results suggested that comorbid T2DM in patients with HFpEF may reduce exercise capacity, HR response, peripheral oxygen extraction, and ventilation efficiency. These results may help identify cardiovascular phenotypes of HFpEF complicated with T2DM and intervention targets for improving exercise intolerance.
Appendix
Available only for authorised users
Literature
1.
Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123–33.PubMedCrossRef
2.
Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the framingham heart study. Circulation. 2002;106:3068–72.PubMedCrossRef
3.
Shimokawa H, Miura M, Nochioka K, Sakata Y. Heart failure as a general pandemic in Asia. Eur J Heart Fail. 2015;17:884–92.PubMedCrossRef
4.
Zhou B, Lu Y, Hajifathalian K, Bentham J, Di Cesare M, Danaei G, et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513–30.CrossRef
5.
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.PubMedCrossRef
6.
Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the cardiovascular health study. J Am Coll Cardiol. 2007;49:972–81.PubMedCrossRef
7.
Klapholz M, Maurer M, Lowe AM, Messineo F, Meisner JS, Mitchell J, et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York heart failure registry. J Am Coll Cardiol. 2004;43:1432–8.PubMedCrossRef
8.
Tribouilloy C, Rusinaru D, Mahjoub H, Tartière JM, Kesri-Tartière L, Godard S, et al. Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year study. Heart. 2008;94:1450–5.PubMedCrossRef
9.
Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, et al. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. Circ Heart Fail. 2015;8:286–94.PubMedCrossRef
10.
Nesti L, Pugliese NR, Sciuto P, De Biase N, Mazzola M, Fabiani I, et al. Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes. Cardiovasc Diabetol. 2021;20:124.PubMedPubMedCentralCrossRef
11.
Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64:541–9.PubMedPubMedCentralCrossRef
12.
Wei M, Gibbons LW, Kampert JB, Nichaman MZ, Blair SN. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med. 2000;132:605–11.PubMedCrossRef
13.
Sugita Y, Ito K, Sakurai S, Sakai S, Kuno S. Epicardial adipose tissue is tightly associated with exercise intolerance in patients with type 2 diabetes mellitus with asymptomatic left ventricular structural and functional abnormalities. J Diabetes Complicat. 2020;34: 107552.CrossRef
14.
Abudiab MM, Redfield MM, Melenovsky V, Olson TP, Kass DA, Johnson BD, et al. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail. 2013;15:776–85.PubMedPubMedCentralCrossRef
15.
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of Left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29:277–314.PubMedCrossRef
16.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145:e876–94.PubMed
17.
Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the heart failure association (HFA) of the European society of cardiology (ESC). Eur Heart J. 2019;40:3297–317.PubMedCrossRef
18.
Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212–28.PubMedPubMedCentralCrossRef
19.
World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1–253.
20.
Du Bois D, Du Bois EF, Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known 1916. Nutrition. 1989;5:303–11.PubMed
21.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef
22.
Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S, Kikuchi K, et al. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis. 2013;61:197–203.PubMedCrossRef
23.
World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. No. WHO/NMH/NHD/MNM/11.1. Geneva: World Health Organization; 2011.
24.
Matsuzawa Y. Metabolic syndrome–definition and diagnostic criteria in Japan. J Atheroscler Thromb. 2005;12:301.PubMedCrossRef
25.
Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anat Valid Method Circ. 1977;55:613–8.
26.
Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American society of echocardiography endorsed by the European association of echocardiography, a registered branch of the European society of cardiology, and the Canadian society of echocardiography. J Am Soc Echocardiogr. 2010;23:685–713.PubMedCrossRef
27.
Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2013;14:611–44.PubMedCrossRef
28.
Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American society of echocardiography developed in collaboration with the society for cardiovascular magnetic resonance. J Am Soc Echocardiogr. 2017;30:303–71.PubMedCrossRef
29.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.PubMedCrossRef
30.
To AC, Flamm SD, Marwick TH, Klein AL. Clinical utility of multimodality LA imaging: assessment of size, function, and structure. JACC Cardiovasc Imaging. 2011;4:788–98.PubMedCrossRef
31.
Kosmala W, Wong C, Kuliczkowska J, Leano R, Przewlocka-Kosmala M, Marwick TH. Use of body weight and insulin resistance to select obese patients for echocardiographic assessment of subclinical left ventricular dysfunction. Am J Cardiol. 2008;101:1334–40.PubMedCrossRef
32.
Morris DA, Takeuchi M, Krisper M, Köhncke C, Bekfani T, Carstensen T, et al. Normal values and clinical relevance of left atrial myocardial function analysed by speckle-tracking echocardiography: multicentre study. Eur Heart J Cardiovasc Imaging. 2015;16:364–72.PubMedCrossRef
33.
Iacobellis G, Sharma AM. Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des. 2007;13:2180–4.PubMedCrossRef
34.
Tanaka K, Takeshima N, Kato T, Niihata S, Ueda K. Critical determinants of endurance performance in middle-aged and elderly endurance runners with heterogeneous training habits. Eur J Appl Physiol Occup Physiol. 1990;59:443–9.PubMedCrossRef
35.
Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol. 1985;1986(60):2020–7.
36.
Laforgia P, Bandera F, Alfonzetti E, Guazzi M. Exercise chronotropic incompetence phenotypes the level of cardiovascular risk and exercise gas exchange impairment in the general population. an analysis of the Euro-ex prevention trial. Eur J Prev Cardiol. 2020;27:526–35.PubMedCrossRef
37.
Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med. 1999;341:1351–7.PubMedCrossRef
38.
Newton RL, Han H, Johnson WD, Hickson DA, Church TS, Taylor HA, et al. Steps/day and metabolic syndrome in African American adults: the jackson heart study. Prev Med. 2013;57:855–9.PubMedPubMedCentralCrossRef
39.
Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc. 2014;15:95–101.PubMedCrossRef
40.
Haykowsky MJ, Nicklas BJ, Brubaker PH, Hundley WG, Brinkley TE, Upadhya B, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail. 2018;6:640–9.PubMedPubMedCentralCrossRef
41.
Mauricio R, Patel KV, Agusala V, Singh K, Lewis A, Ayers C, et al. Sex differences in cardiac function, biomarkers and exercise performance in heart failure with preserved ejection fraction: findings from the RELAX trial. Eur J Heart Fail. 2019;21:1476–9.PubMedCrossRef
42.
Carbone S, Canada JM, Buckley LF, Trankle CR, Dixon DL, Buzzetti R, et al. Obesity contributes to exercise intolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2016;68:2487–8.PubMedPubMedCentralCrossRef
43.
Pandey A, Kitzman DW, Brubaker P, Haykowsky MJ, Morgan T, Becton JT, et al. Response to endurance exercise training in older adults with heart failure with preserved or reduced ejection fraction. J Am Geriatr Soc. 2017;65:1698–704.PubMedPubMedCentralCrossRef
44.
Zakeri R, Borlaug BA, McNulty SE, Mohammed SF, Lewis GD, Semigran MJ, et al. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail. 2014;7:123–30.PubMedCrossRef
45.
Bekfani T, Pellicori P, Morris DA, Ebner N, Valentova M, Steinbeck L, et al. Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life. Int J Cardiol. 2016;222:41–6.PubMedCrossRef
46.
Parcha V, Patel N, Kalra R, Bhargava A, Prabhu SD, Arora G, et al. Clinical, demographic, and imaging correlates of anemia in heart failure with preserved ejection fraction (from the RELAX Trial). Am J Cardiol. 2020;125:1870–8.PubMedPubMedCentralCrossRef
47.
Pugliese NR, Paneni F, Mazzola M, De Biase N, Del Punta L, Gargani L, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail. 2021;23:1858–71.PubMedCrossRef
48.
Palau P, Seller J, Domínguez E, Sastre C, Ramón JM, de La Espriella R, et al. Effect of β-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol. 2021;78:2042–56.PubMedCrossRef
49.
Sone H, Ito H, Ohashi Y, Akanuma Y, Yamada N. Obesity and type 2 diabetes in Japanese patients. Lancet. 2003;361:85.PubMedCrossRef
50.
DeFronzo RA, Lilly lecture,. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM Diabetes. 1987;1988(37):667–87.
51.
Wehner GJ, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN, et al. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie. Eur Heart J. 2020;41:1249–57.PubMedCrossRef
52.
Zhu S, Lin Y, Zhang Y, Wang G, Qian M, Gao L, et al. Prognostic relevance of left atrial function and stiffness in heart failure with preserved ejection fraction patients with and without diabetes mellitus. Front Cardiovasc Med. 2022;9: 947639.PubMedPubMedCentralCrossRef
53.
Vukomanovic V, Suzic-Lazic J, Celic V, Cuspidi C, Grassi G, Galderisi M, et al. Is there association between left atrial function and functional capacity in patients with uncomplicated type 2 diabetes. Int J Cardiovasc Imaging. 2020;36:15–22.PubMedCrossRef
54.
Santos AB, Roca GQ, Claggett B, Sweitzer NK, Shah SJ, Anand IS, et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9: e002763.PubMedPubMedCentralCrossRef
55.
Nadruz W, West E, Sengeløv M, Santos M, Groarke JD, Forman DE, et al. Prognostic value of cardiopulmonary exercise testing in heart failure with reduced, midrange, and preserved ejection fraction. J Am Heart Assoc. 2017;6:e006000.PubMedPubMedCentralCrossRef
56.
Haykowsky MJ, Brubaker PH, John JM, Stewart KP, Morgan TM, Kitzman DW. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol. 2011;58:265–74.PubMedPubMedCentralCrossRef
57.
Bhella PS, Prasad A, Heinicke K, Hastings JL, Arbab-Zadeh A, Adams-Huet B, et al. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:1296–304.PubMedPubMedCentralCrossRef
58.
Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588–95.PubMedPubMedCentralCrossRef
59.
Astrand PO, Cuddy TE, Saltin B, Stenberg J. Cardiac output during submaximal and maximal work. J Appl Physiol. 1964;19:268–74.PubMedCrossRef
60.
Klaassen SHC, Liu LCY, Hummel YM, Damman K, van der Meer P, Voors AA, et al. Clinical and hemodynamic correlates and prognostic value of VE/VCO2 slope in patients with heart failure with preserved ejection fraction and pulmonary hypertension. J Card Fail. 2017;23:777–82.PubMedCrossRef
61.
Tantucci C, Bottini P, Dottorini ML, Puxeddu E, Casucci G, Scionti L, et al. Ventilatory response to exercise in diabetic subjects with autonomic neuropathy. J Appl Physiol. 1985;1996(81):1978–86.
62.
Abe T, Yokota T, Fukushima A, Kakutani N, Katayama T, Shirakawa R, et al. Type 2 diabetes is an independent predictor of lowered peak aerobic capacity in heart failure patients with non-reduced or reduced left ventricular ejection fraction. Cardiovasc Diabetol. 2020;19:142.PubMedPubMedCentralCrossRef
63.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.PubMedCrossRef
64.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail. 2022;28:e1–167.CrossRef
65.
Tsutsui H, Ide T, Ito H, Kihara Y, Kinugawa K, Kinugawa S, et al. JCS/JHFS 2021 Guideline focused update on diagnosis and treatment of acute and chronic heart failure. J Card Fail. 2021;27:1404–44.PubMedCrossRef
66.
Kemps HM, Thijssen EJ, Schep G, Sleutjes BT, De Vries WR, Hoogeveen AR, et al. Evaluation of two methods for continuous cardiac output assessment during exercise in chronic heart failure patients. J Appl Physiol. 1985;2008(105):1822–9.
67.
Pugliese NR, Fabiani I, Santini C, Rovai I, Pedrinelli R, Natali A, et al. Value of combined cardiopulmonary and echocardiography stress test to characterize the haemodynamic and metabolic responses of patients with heart failure and mid-range ejection fraction. Eur Heart J Cardiovasc Imaging. 2019;20:828–36.PubMedCrossRef
Metadata
Title
Association of complication of type 2 diabetes mellitus with hemodynamics and exercise capacity in patients with heart failure with preserved ejection fraction: a case–control study in individuals aged 65–80 years
Authors
Yousuke Sugita
Katsuhiko Ito
Yui Yoshioka
Satoshi Sakai
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-023-01835-2

Other articles of this Issue 1/2023

Cardiovascular Diabetology 1/2023 Go to the issue

Research

Triglyceride-glucose index is associated with recurrent revascularization in patients with type 2 diabetes mellitus after percutaneous coronary intervention

Research

Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review

Research

Cumulative exposure to high remnant-cholesterol concentrations increases the risk of cardiovascular disease in patients with hypertension: a prospective cohort study

Research

Timing of SGLT2i initiation after acute myocardial infarction

Research

Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study

Methodology

Association between triglyceride glucose index and arterial stiffness and coronary artery calcification: a systematic review and exposure-effect meta-analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits